Castle Biosciences (CSTL) Other Working Capital Changes (2021)

Castle Biosciences has reported Other Working Capital Changes for 6 years, with the latest figure at -$59000.0 in Q2 2026.

• Quarterly Other Working Capital Changes rose 82.8% year-over-year to -$59000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$637000.0 (up 63.09% YoY) and the FY2025 annual result came in at -$1.3 million, up 1.09% from the prior year.
• Other Working Capital Changes advanced to -$59000.0 in Q2 2026 per CSTL's latest filing, from -$172000.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $6.7 million in Q1 2026 and troughed at -$4.0 million in Q4 2025.
• A 5-year average of $604944.4 and a median of $353500.0 in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes surged 568.49% in 2023, then tumbled 419.26% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$49000.0 in 2022, then plunged by 391.84% to -$241000.0 in 2023, then tumbled by 76.76% to -$426000.0 in 2024, then jumped by 50.94% to -$209000.0 in 2025, then soared by 71.77% to -$59000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$59000.0, -$172000.0, and -$209000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.